Loading clinical trials...
Loading clinical trials...
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain
The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.
* reduced treatment adherence due to metabolic side effects * suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers * randomized trial of switch from previous drugs to aripiprazole
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Start Date
December 1, 2008
Primary Completion Date
March 1, 2012
Completion Date
March 1, 2012
Last Updated
December 5, 2013
28
ACTUAL participants
aripiprazole
DRUG
Lead Sponsor
Seoul National University Hospital
Collaborators
NCT06993103
NCT06360666
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions